Press Releases from Max-Planck-Innovation GmbH (3 total)
Max Planck Innovation awards license for actin marker LifeAct
Max Planck Innovation and ibidi sign license agreement for cytoskeleton research.
Max Planck Innovation GmbH, the technology transfer organization of the Max Planck Society, has awarded an exclusive license for LifeAct to ibidi GmbH, a provider of cell analysis products, located in Martinsried near Munich. The novel peptide allows for actin, an important protein, to be made visible in living cells without disturbing the actin dependent processes. Therefore, cells as well…
Max Planck Innovation awards license to Solexel for an innovative method to deve …
Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society, Germany’s leading basic research organization, has signed a co-exclusive license agreement for its Porous-Silicon-Process (PSI process) technology with Solexel, Inc., a company focusing on the development and commercialisation of high-efficiency thin-film photovoltaic arrays and solar modules.
Fueled by high energy prices, the market for solar cells is experiencing an enormous boost. The rising demand is currently leading…
Max Planck Innovation’s Drug Discovery and Development Center Wins BioPharma S …
Project will receive €20 million in funding from the BMBF
September 30, 2008 - Max Planck Innovation GmbH, the technology transfer agency of the Max Planck Society (MPG), announces today that its concept for a novel Drug Discovery and Development Center (DDC) will receive €20 million in funding from the German Ministry of Education and Research (BMBF) through its initiative “BioPharma – The strategy competition for medicine of the future”. The…
